Fig. 2

The therapeutic effect of GC on existing metabolic and liver damage was studied in four groups of C57BL/6 mice. Mice in group D received the vehicle alone; Group E received Dexamethasone; Group F received a combination of Dexamethasone with GC; mice in group G received Dexamethasone for six weeks followed by two weeks of Dexamethasone with GC. Mice were followed for fasting glucose levels (a); postprandial glucose levels as manifested by glucose tolerance test (b); serum insulin levels (c); serum triglyceride levels (d); AST and ALT liver enzymes (e); liver histology (H&E X10) (f); hepatic triglycerides content (g); and for serum levels of IL10 and IL17 (h) (**p < 0.01, *p < 0.05)